Immutep updates the market on TACTI-mel, TACTI-002 and IMP761

Highlights

• Positive, more mature data from its ongoing TACTI-mel Phase I clinical trial of the Company’s lead product candidate, eftilagimod alpha (“efti” or “IMP321”) in combination with KEYTRUDA® (pembrolizumab) in 24 melanoma patients.
• The first patient had been dosed in a new Phase II clinical trial (TACTI-002) which will evaluate the combination of efti and KEYTRUDA (pembrolizumab) in head and neck squamous cell carcinoma (2^nd line) and non-small cell lung cancer (1^st and 2^nd line).
• Positive results from its preclinical study of IMP761, a novel LAG-3 agonist antibody being developed for the treatment of autoimmune disease.

Immutep has announced positive, more mature data from its ongoing TACTI-mel Phase I clinical trial of the Company’s lead product candidate, eftilagimod alpha (“efti” or “IMP321”) in combination with KEYTRUDA® (pembrolizumab) in 24 melanoma patients. The data was presented at the World Immunotherapy Congress 2019 in San Diego USA, by Dr. Frederic Triebel, Immutep’s Chief Scientific Officer and Chief Medical Officer.

Immutep also announced that the first patient had been dosed in a new Phase II clinical trial (TACTI-002) which will evaluate the combination of efti and KEYTRUDA (pembrolizumab) in head and neck squamous cell carcinoma (2^nd line) and non-small cell lung cancer (1^st and 2^nd line).

The TACTI-002 trial is being conducted in collaboration with Merck & Co., Inc., Kenilworth, NJ, USA (known as “MSD” outside the United States and Canada), as announced to the market in March 2018. The study will take place in up to 109 patients in up to 13 study centres across Australia, Europe and the United States.

Finally, Immutep announced positive results from its preclinical study of IMP761, a novel LAG-3 agonist antibody being developed for the treatment of autoimmune disease. The results were presented at the 14th Congress of European Crohn’s and Colitis Organisation (ECCO) Conference in Denmark.

Consistent with earlier in vitro studies conducted by Immutep on the immunosuppressive activity of IMP761, this new study in a non-human primate animal model showed that IMP761 decreases inflammatory T cell infiltration induced by intra-dermal injection of an antigen.

Full announcements below:

• Immutep presented at the World Immunotherapy Congress USA 2019
• Immutep doses First Patient in TACTI-002 Phase II Trial
• IMP761 results presented at ECCO conference

Register Interest